Publication Details

Category Text Publication
Reference Category Journals
DOI 10.1172/jci23792
Title (Primary) CD137-mediated immunotherapy for allergic asthma
Author Polte, T.; Foell, J.; Werner, C.; Hoymann, H.G.; Braun, A.; Burdach, S.; Mittler, R.S.; Hansen, G.
Source Titel Journal of Clinical Investigation
Year 2006
Department IMMU
Volume 116
Issue 4
Page From 1025
Page To 1036
Language englisch
Abstract The prevalence of asthma continues to increase. Asthma is caused by a Th2 cell-driven immune response. Its optimal treatment remains a challenge, and a sufficient immunotherapeutic approach to treating asthma has yet to be found. Using a murine asthma model, we show that a single injection of an anti-CD137 (4-1BB) mAb prevents the development of airway hyperreactivity, eosinophilic airway inflammation, excessive mucus production, and elevated IgE during the observation period of 7 weeks. Most importantly, even established disease is completely reversed by anti-CD137 mAb administration. The protection is associated with markedly reduced Th2 cytokine production and increased secretion of the Th1 cytokine IFN-gamma. While B lymphocytes are partly depleted, the number of CD8(+) T cells is increased. Blockade of IFN-gamma and depletion of CD8(+) T cells during treatment with anti-CD137 mAb reduces in part but does not abrogate the protective effect of CD137 mAb. In contrast, CD137 mAb-mediated CD4(+) T cell anergy is critical for the observed effects, since transfer of CD4(+) T cells from CD137 mAb-treated mice conveyed protection. These data demonstrate, for the first time to our knowledge, the capacity of anti-CD137 mAb to ameliorate allergic asthma, and they indicate CD137 as a possible target for therapeutic intervention in this disease
Persistent UFZ Identifier
Polte, T., Foell, J., Werner, C., Hoymann, H.G., Braun, A., Burdach, S., Mittler, R.S., Hansen, G. (2006):
CD137-mediated immunotherapy for allergic asthma
J. Clin. Invest. 116 (4), 1025 - 1036 10.1172/jci23792